Human Reproductive Technologies Market Analysis (2020-2027)

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. HUMAN REPRODUCTIVE TECHNOLOGIES MARKET ANALYSIS(2020-2027) • Human Reproductive Technologies Market, By Technology (Infertility Drugs, Contraceptive Drugs and Devices), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

3. Human reproductive technologies include, Assisted Reproductive Technology (ART), prognostics, contraception, and same-sex procreation. ART aids in the treatment of low fertility or infertility using artificial insemination, artificial reproduction, cloning, cytoplasmic transfer, fertility medication, hormone treatment, and others. The global human reproductive technologies market is estimated to account for US$ 28,426.7 Mn in 2019 in terms of value and US$ 34,228.3 Mn by the end of 2027.

4. Global Human Reproductive Technologies Market: Drivers • Increasing prevalence of maternal mortality is expected to propel growth of the global human reproductive technologies market over the forecast period. For instance, according to Maternal Mortality: 1990 to 2015 Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division, Sub-Saharan Africa recorded the highest ratio or maternal mortality, at 555 per 100, 000 live births, from 1990 to 2015. Moreover, the United Nations is focused on achieving the Sustainable Development Goals 2015 - 2030 global maternal mortality ratio target of less than 70 per 100 000 live births. • Moreover, decreasing birth rate is also expected to aid in growth of the market. For instance, according to National Vital Statistics System, the provisional number of births for the U.S. in 2018 was 3,788,235, registering a decrease of 2% from 2017 and the lowest number of births in 32 years. • North America held dominant position in the global human reproductive technologies market in 2019, accounting for 46.1% share in terms of value, followed by Europe and Asia Pacific, respectively.

5. Figure 1. Global Human Reproductive Technologies Market Share (%), by Value, by Region, 2019

6. Global Human Reproductive Technologies Market: Restraints • Limited insurance coverage for ART is expected to hinder growth of the market. ART is a relatively new and yet to be fully proven process in many countries. Such a status causes insurance companies to be apprehensive about covering expenses. For instance, in Canada, there is limited fund for IVF and intracytoplasmic sperm injection and hence infertile couples have to bear the cost of treatment. The average cost for infertility treatment in Canada is quite expensive and ranges from between US$ 10,000 to US$ 20,000. • Moreover, infertility treatments may not prove to be conclusive or effective and thereby need to be repeated sometimes. Such a risk of repetition of procedures negatively affects the decision of the consumers and limits market growth.

8. Global Human Reproductive Technologies Market: Opportunities • .Increasing rate of literacy is expected to offer lucrative growth opportunities for players in the global human reproductive technologies market. For instance, according to United Nations Children's Fund, globally, the youth literacy rate increased from 83% to 91% during 1985-2018. • Moreover, R&D in male birth control pill is also expected to aid in growth of the market. For instance, in March 2018, researchers from the University of Washington presented positive results from a small clinical trial of 100 men for a male birth control pill that inhibits testosterone production. • The global human reproductive technologies market was valued at US$ 28,426.7 Mn in 2019 and is forecast to reach a value of US$ 34,228.3 Mn by 2027 at a CAGR of 2.4% between 2020 and 2027.

9. Figure 2. Global Human Reproductive Technologies Market Value (US$ Bn), and Y-o-Y Growth (%), 2019-2027

10. Market Trends/Key Takeaways • Increasing population is expected to propel demand for emergency human reproductive technologies. For instance, according to projections by Population Reference Bureau (PRB) included in the 2018 World Population Data Sheet, the world population is expected to reach 9.9 billion by 2050, up 2.3 billion or 29% from an estimated 7.6 billion people in 2018. • However, low adoption of emergency human reproductive technologies in emerging economies is expected to act as a drag for the demand. For instance, according to PRB’s 2019 Family Planning Data Sheet, fewer than 15% of married women of reproductive age use a modern human reproductive technologies in Democratic Republic of the Congo.

11. Global Human Reproductive Technologies Market: Competitive Landscape • Major players operating in the global human reproductive technologies include, Abbott Laboratories, Evofem Biosciences, Inc., Actavis Generics (Teva Pharmaceutical Industries Ltd.), Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Uniprix, Gavis Pharmaceuticals (Lupin Limited), Sandoz International GmbH, Aurobindo Pharma Limited, HRA Pharma, SA, Mankind Pharma, Cryos USA, Merck & Co, Bayer HealthCare AG, Church & Dwight, Co. Inc., Allergan, Pfizer, Inc., Agile Therapeutics Inc., BioSante Pharmaceuticals Inc., Mayer Laboratories, Inc., Pantarhei Bioscience B.V., Cook Medical, Inc., Ferring Pharmaceuticals, Johnson & Johnson, Daré Bioscience, Inc., and Merck Serono.

12. Global Human Reproductive Technologies Market: Key Developments Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, Evofem Biosciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel used to prevent pregnancy in females of reproductive potential for use as an on-demand method of contraception. Major players in the market are also focused on adopting partnership strategies to expand their product portfolio. For instance, in May 2020, Daré Bioscience, Inc., a developer of women’s health solutions partnered with Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, under which Health Decisions will exclusively provide CRO services within the U.S. to support R&D of Daré’s pipeline of contraception, fertility, and gynecological disorders products.

13. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now Reference: https://www.coherentmarketinsights.com/market-insight/human-reproductive-technologies-market-3921

14. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

15. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

16. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/